Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 154 No. 2 (2024)

Successful treatment of immune checkpoint inhibitor-related periaortitis

  • Elias D. Bührer
  • Ian L. Alberts
  • Lisa Christ
  • Berna C. Özdemir
DOI
https://doi.org/10.57187/s.3631
Cite this as:
Swiss Med Wkly. 2024;154:3631
Published
15.02.2024

Summary

We report a 64-year-old patient with melanoma receiving ipilimumab and nivolumab therapy who presented with a periaortic soft tissue mass around the abdominal aorta on restaging fluorodeoxyglucose positron emission tomography/computed tomography imaging. Clinical, laboratory, and radiologic findings resulted in a diagnosis of immune checkpoint inhibitor-related periaortitis. Periaortitis is a rare disease presenting with fibro-inflammatory tissue around the aorta and may lead to serious complications. Immune checkpoint inhibitors were discontinued, and the patient was treated with glucocorticoids, leading to a complete resolution of the periaortitis. To our knowledge, this is only the third reported case of immune checkpoint inhibitor-related periaortitis.

References

  1. Marvisi C, Accorsi Buttini E, Vaglio A. Aortitis and periaortitis: the puzzling spectrum of inflammatory aortic diseases. Presse Med. 2020 Apr;49(1):104018. 10.1016/j.lpm.2020.104018 DOI: https://doi.org/10.1016/j.lpm.2020.104018
  2. Mizushima I, Kasashima S, Fujinaga Y, Kawano M, Ishizaka N. IgG4-related periaortitis/periarteritis: an under-recognized condition that is potentially life-threatening. Mod Rheumatol. 2019 Mar;29(2):240–50. 10.1080/14397595.2018.1546367 DOI: https://doi.org/10.1080/14397595.2018.1546367
  3. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020 Jul;11(1):3801. 10.1038/s41467-020-17670-y DOI: https://doi.org/10.1038/s41467-020-17670-y
  4. Roy AK, Tathireddy HR, Roy M. Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. BMJ Case Rep 2017/bcr-2017-221852. 10.1136/bcr-2017-221852 DOI: https://doi.org/10.1136/bcr-2017-221852
  5. Hotta M, Naka G, Minamimoto R, Takeda Y, Hojo M. Nivolumab-induced periaortitis demonstrated by FDG PET/CT. Clin Nucl Med. 2020 Nov;45(11):910–2. 10.1097/RLU.0000000000003215 DOI: https://doi.org/10.1097/RLU.0000000000003215
  6. Gianfreda D, Superchi E, Peyronel F, Mazzariol M, Vaglio A. Chronic periaortitis: A clinical approach. Rev Med Interne. 2023 Feb;44(2):79–84. 10.1016/j.revmed.2022.11.009 DOI: https://doi.org/10.1016/j.revmed.2022.11.009
  7. Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sar- coidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol. 2018 Aug;13(8):1076–82. 10.1016/j.jtho.2018.04.031 DOI: https://doi.org/10.1016/j.jtho.2018.04.031
  8. Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015 Jun;74(6):1171–7. 10.1136/annrheumdis-2014-206605 DOI: https://doi.org/10.1136/annrheumdis-2014-206605
  9. Joob B, Wiwanitkit V. Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis and nivolumab. World J Clin Cases. 2022 Dec;10(35):13146–7. 10.12998/wjcc.v10.i35.13146 DOI: https://doi.org/10.12998/wjcc.v10.i35.13146
  10. Terashima T, Iwami E, Shimada T, Kuroda A, Matsuzaki T, Nakajima T, et al. IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report. BMC Pulm Med. 2020 Apr;20(1):104. 10.1186/s12890-020-1150-x DOI: https://doi.org/10.1186/s12890-020-1150-x
  11. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2045–51. 10.1161/ATVBAHA.108.179705 DOI: https://doi.org/10.1161/ATVBAHA.108.179705
  12. Jois RN, Gaffney K, Marshall T, Scott DG. Chronic periaortitis. Rheumatology (Oxford). 2004 Nov;43(11):1441–6. 10.1093/rheumatology/keh326 DOI: https://doi.org/10.1093/rheumatology/keh326